Work

Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?

Year: 2019

Type: article

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(19)30085-3

Author: James Chih-Hsin Yang

Institutions: National Taiwan University, National Taiwan University Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2938851145

FWCI: 0.184

Cites: 10

Cited by: 4

Related to: 10